HomeClinical TopicsFDA approves first drug for postpartum depression

FDA approves first drug for postpartum depression

Author(s):

On March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression. Zulresso will be available only through a restricted program that requires the drug be administered by a healthcare provider in a certified health care facility.

Read more at FDA.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

NP taking pregnant woman's blood pressure

AHA: It’s Safe to Treat High Blood Pressure During Pregnancy

High blood pressure during pregnancy can present significant risks to mother and child, but practitioners have sometimes be hesitant to prescribe blood pressure medication...